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Abstract
Background:  We had earlier used the comparison of RAPD (Random Amplification of
Polymorphic DNA) DNA fingerprinting profiles of tumor and corresponding normal DNA to
identify genetic alterations in primary human glial tumors. This has the advantage that DNA
fingerprinting identifies the genetic alterations in a manner not biased for locus.
Methods: In this study we used RAPD-PCR to identify novel genomic alterations in the astrocytic
tumors of WHO grade II (Low Grade Diffuse Astrocytoma) and WHO Grade IV (Glioblastoma
Multiforme). Loss of heterozygosity (LOH) of the altered region was studied by microsatellite and
Single Nucleotide Polymorphism (SNP) markers. Expression study of the gene identified at the
altered locus was done by semi-quantitative reverse-transcriptase-PCR (RT-PCR).
Results: Bands consistently altered in the RAPD profile of tumor DNA in a significant proportion
of tumors were identified. One such 500 bp band, that was absent in the RAPD profile of 33% (4/
12) of the grade II astrocytic tumors, was selected for further study. Its sequence corresponded
with a region of FAT, a putative tumor suppressor gene initially identified in Drosophila. Fifty percent
of a set of 40 tumors, both grade II and IV, were shown to have Loss of Heterozygosity (LOH) at
this locus by microsatellite (intragenic) and by SNP markers. Semi-quantitative RT-PCR showed
low FAT mRNA levels in a major subset of tumors.
Conclusion: These results point to a role of the FAT in astrocytic tumorigenesis and demonstrate
the use of RAPD analysis in identifying specific alterations in astrocytic tumors.
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Background
Astrocytic tumors are the most frequent human gliomas;
they are the second most common cause of cancer mortal-
ity in young adults after leukemia. WHO has classified
astrocytic tumors into 4 grades [1]. Grade I (Pilocytic
Astrocytomas) have a benign outcome and have genetic
pathways that differ from the three higher grades. How-
ever Grades II to IV follow the same lineage of progression
and Grade II (Low-grade Diffuse Astrocytomas, DA) have
an inherent tendency to progress to grade III (Anaplastic
Astrocytoma, AA) and grade IV (Glioblastoma Multi-
forme, GBM)[2,3]. Molecular alterations associated with
these histopathological classes have also been identified
and studied extensively. The median survival time of
Grade II and IV tumors is 6 years and 1 year respectively
[4], and over the years, not much has changed regarding
their outcome. Malignant transformation of glial cells is a
complex process[5] that is still incompletely understood
[6,7].
We had earlier used RAPD-DNA fingerprinting techniques
[8] to identify alterations in tumor DNA in a manner not
selected for locus [9,10]. While RAPD primers define dis-
tinct loci, their selection is random and not locus based.
We have also used this technique to measure the extent of
intra-tumor genetic heterogeneity [11,12] and genomic
instability in high and low grade tumors [13] and the role
of repeat sequences in the generation of instability
[14,15]. This technique scans the whole genome for com-
plimentarity at any locus and thus enhances the chances
of detecting novel altered genomic regions in tumors. Fur-
thermore, RAPD screening can be performed on a small
amount of tumor DNA (50–100 ng of DNA per PCR).
This is important because of the possibility of shearing
and low retrieval after extracting tumor DNA from cryo-
stat sections. In most of our earlier studies we concen-
trated on genomic instability i.e. the RAPD changes,
which varied from tumor to tumor. In this study, we have
used the RAPD-PCR technique to identify and character-
ize novel alterations in the human astrocytic tumors of
WHO grade II (DA) and grade IV (GBM) using normal
leucocyte DNA of the same patient as control. The altered
bands (gained, amplified or lost) in the tumor RAPD pro-
files are used to document, quantify and characterize the
nature of alterations. We focused on the alterations that
were common to a significant proportion (more than
25%) of the astrocytic tumors studied and characterized
one of them. This was done in order to identify genomic
changes that may be significant to the tumorigenic proc-
ess.
We initially used five different primers to compare the
RAPD profile of 23 astrocytic tumors (12 grade II and 11
grade IV) with their corresponding normal leucocyte
DNA. One altered band, which was absent in the RAPD
profile of 33% of the Grade II tumors studied, was found
to be homologous to the tumor suppressor gene 'FAT' on
chromosome 4q34-35. Heterozygosity analysis per-
formed in a larger set of 40 tumors and gene expression
studies [by semi quantitative reverse transcriptase (RT)-
PCR] indicate that the FAT may be involved as a tumor
suppressor gene in primary human glioma.
Methods
The work has been approved by the ethics committee of
our institute. Samples were collected with prior informed
consent from each patient.
Samples processing and DNA extraction
Samples of WHO grade II and IV human astrocytic tumors
were obtained from patients who were undergoing sur-
gery at Neurosurgery Operation Theatre of All India Insti-
tute of Medical Sciences (AIIMS), India. The number of
Grade III tumors we get from our clinical collaborators are
much fewer than Grade II and Grade IV. Hence we chose
grade II as an example of Low Grade Astrocytoma and
Grade IV as an example of High Grade Astrocytoma. Tis-
sue samples were immediately stored frozen at -70°C.
Cryosectioning was done and only those sections were
taken which showed more than or equal to 80% neoplas-
tic cells. Leucocyte DNA of the same patient was used as a
control. DNA extraction and quantification was done as
described by us previously[11].
RAPD-PCR analysis and scoring of alterations
RAPD-PCR was done with 5 RAPD 10 mer primers, pur-
chased from Genosis, USA (Table 1). PCR was performed
with the precautions described by us earlier[14] in
PTC200 thermal cycler (MJ Research, USA). Products were
resolved in a 1.5% agarose gel, stained with ethidium bro-
mide, visualized on a UV transilluminator and docu-
mented. Scoring of the alteration(s) was done by
comparing the RAPD profile of the normal and tumor
DNA. The alteration(s) observed were confirmed by three
independent experiments and scoring done by 2 inde-
pendent observers (KC and AM). Twenty three astrocytic
tumors (12 grade II and 11 grade IV) were studied by this
technique.
Characterization of altered fragment
The RAPD gel of the samples (paired tumor and control
DNA) showing an altered band profile in tumors was
transferred to a nylon membrane for Southern analy-
sis[14]. The altered fragment from one of the normal sam-
ple from a separate gel was excised and eluted from the gel
using Qia quick gel extraction kit (Qiagen, USA). The
eluted band was PCR radiolabelled and used as probe for
Southern hybridization of a gel containing paired tumor
and control DNA PCR products showing alteration. The
eluted band was then cloned in a pGEMT-Easy vector sys-BMC Cancer 2009, 9:5 http://www.biomedcentral.com/1471-2407/9/5
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Table 1: Details of the RAPD primers, Microsatellite markers and SNP markers used.
RAPD Primers
Serial no. RAPD Primer ID Sequence (5'-3') GC content (%age) Annealing temp. MgCl2 (mM)
1. 80/07 GCACGCCGGA 80 38°C 3.0
2. 80/01 GCACCCGACG 80 35°C 3.0
3. 70/04 CGCATTCCGC 80 35°C 3.0
4. 70/01 CATCCCGAAC 70 38°C 3.0
5. 60/31 TGCGCGATCG 70 38°C 3.0
Microsatellite markers
Serial no. Microsatellite marker 
ID
Primer sequences (5'-3') Annealing temp. Product size (bp)
1. D4S3173 Left Primer: TTGGAGTCCCTGAAGGACC
Right primer: TACAAACACCAAGCCCCTTC
57°C 103–104
2. D4S2827 Left Primer: GACGGGAGAGAAAATGCATT
Right primer: 
TCAATAAGCACCAAAACTACTCAG
55°C 132–133
3. D4S1295 Left 
Primer:TAACAAAACCATCTCCAAACTTCT
C
Right primer: 
GTGGACAGTACAACACAGTTGAC
57°C 170
4. D4S2643 Left 
Primer:TTGTCCAATAACTCTTTTCCTAAC
A
Right primer: 
CTGATTCCTATATCAATCTTGGCC
57°C 179–180
5. D4S2672 Left Primer: 
TAAAGATGTGATTTGTATTGCATTG
Right primer: 
AGTTTCAGCCTCTCAAAATTTCA
57°C 199–200
SNP markers
Serial no. SNP Cluster ID Primer sequences (5'-3') Annealing temp. Product size (bp) Restriction 
endonucleases
1. rs2276930 Left primer: 
GCCGTAACTAACCTCGG
CATC
Right primer: 
GCCTCACGCTCCCCGAG
CGCA
61°C 270 BstN1
2. rs3733414 Left primer: 
CGCCCCAGTTCTCTTCT
GT
Right primer: 
TGTTGTTACTTCAAGTTC
AAAATGG
60.8°C 290 Rsa1BMC Cancer 2009, 9:5 http://www.biomedcentral.com/1471-2407/9/5
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tem (Promega, USA). The insert was again confirmed by
Southern hybridization by using the gel eluted radiola-
beled fragment as probe. Sequencing of the cloned frag-
ment was done by using Thermosequenase kit
(Amersham, USA) with fluorescent labeled dideoxy
nucleotides on an ABI-Prism automated DNA sequencer
(Appiled Biosystem, USA). Homology search of the
sequences was done using the BLAST search tool with the
human genome sequences database.
Characterization of the RAPD primer binding sites
In order to identify if changes had occurred in the RAPD
primer binding sites, a specific primer pair (forward 5'
ACCCgTgTTTTCCAgCTTT 3' and reverse 5' CTCT-
gCCTCTCgACCAAAAC 3') was designed to amplify the
FAT region corresponding to the altered RAPD band iden-
tified including about 100 bases on either side flanking
the altered band. The PCR using specific primer pair was
done directly from genomic DNA from two sample pairs
(tumor and corresponding normal DNA) shown to have
alteration in the tumors. The PCR product was resolved in
1.5% agarose gel, stained with Ethidium bromide and
documented. The PCR product was eluted from all the
samples (two normal and two tumors) separately from
the gel using Qia quick gel extraction kit (Qiagen, USA)
and sequenced. Homology search of the sequences was
done by BLAST 2 search tool with the FAT sequence to
look for alterations in the RAPD primer binding regions.
Loss of heterozygosity (LOH) studies
LOH analysis of the FAT locus was done using five micro-
satellite markers and ten SNP markers on 40 human astro-
cytic tumors (20 grade II and 20 grade IV). One
microsatellite marker used was intragenic to the FAT gene
and four flanking the gene. All the SNP markers used were
intragenic to the FAT gene.
3. rs455600 Left primer: 
TCATTGACTTTTGCTTTT
CCTAA
Right primer: 
CCAACGAATCAGCAAAG
AAC
60.8°C 299 Acc1
4. rs213090 Left primer: 
GGCAGTTGAAATTTACTT
TATAGTTCT
Right primer: 
AGACTGCAGTGTGCAAT
TCTG
61°C 394 HaeIII
5. rs450320 Left primer: 
CGAAATCCTACTCCTGG
CTTT
Right primer: 
GCATCACTCCTGCTCCT
CAT
60.8°C 349 Hpy1881
6. rs7663350 Left primer: 
TGGTTTTGGTGAAGCATA
AGAA
Right primer: 
AAGTTATCCAGGATTTCA
ATCTCA
60.8°C 400 Sau3A1
7. rs1193110 Left primer: 
AGACCCTTTCAGCCAGTT
CA
Right primer: 
AGTGAGATGAGGCCAGT
GCT
61°C 369 Msp1
8. rs1298865 Left primer: 
TTGTCATCCTTCCTTTTA
GCAA
Right primer: 
GATCCTTCAATGAATATG
TTCTTCTC
60.8°C 400 Dde1
Table 1: Details of the RAPD primers, Microsatellite markers and SNP markers used. (Continued)BMC Cancer 2009, 9:5 http://www.biomedcentral.com/1471-2407/9/5
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Microsatellite Markers: Selection and analysis
Microsatellite markers (one intragenic and two each flank-
ing on both 5' and 3' side of the FAT gene, within 0.2 Mb
of the gene) were selected. The markers studied were
D4S3173, D4S2827, D4S1295, D4S2643 and D4S2672.
The sequences of the forward and reverse primers of the
markers were taken from the NCBI UNISTAT database
and primers were obtained from Research Genetics, Inc,
USA (Table 1).
The PCR cycling conditions and the annealing tempera-
ture were standardized. The PCR product was resolved
onto a 6% denaturing gel containing 7 M Urea cast on the
BioRad midigel apparatus. After the electrophoresis for
visualization and analysis of the bands the gel was stained
with 10 mg% ethidium bromide[16], visualized on UV
transilluminator and documented in Gel Documentation
System (Alpha Innotech Corporation, USA). Each experi-
ment was repeated twice and scoring done by 2 independ-
ent observers (KC and TS).
For heterozygosity analysis the microsatellite pattern of
tumor DNA was compared to its corresponding leucocyte
DNA. Only informative (heterozygous) samples were
considered for LOH analysis. LOH observed with even
one of the marker in the tumor was taken as LOH in the
tumor at the locus.
SNP markers: Selection and analysis
Genotypic and allelic frequency of 365 SNPs present in
FAT  gene was obtained from Ensembl database. SNPs
reported to have a high heterozygosity status were chosen.
Hundred SNPs with high heterozygosity status were
checked for the presence of restriction endonuclease site
using DNA STAR program. We found 30 SNPs with a
restriction site, of which only 10 SNPs were found to have
had a unique restriction site within the polymorphic
region when flanking 400–500 bps. Primers were
designed for each SNP so as to obtain a PCR product of
300–400 bp, which on restriction digestion gave bands of
unequal size. All the primers were commercially synthe-
sized from Integrated DNA Technologies, Inc. (Table 1).
The PCR products were purified by chloroform treatment
followed by ethanol precipitation. The digestion of the
PCR products was done with the appropriate restriction
enzyme and resolved on 2% agarose gel, stained with
ethidium bromide and visualized on UV transilluminator
and documented.
For heterozygosity analysis the SNP-PCR-RFLP pattern of
tumor DNA was compared to its corresponding leucocyte
DNA. For LOH analysis, only those sample pair were con-
sidered in which the normal DNA had shown a hetero-
zygous pattern. For scoring changes, LOH with even one
SNP marker was considered to be indicative of LOH of the
locus for a particular sample. LOH frequency for each SNP
was calculated separately as percentage of all informative
samples for that particular SNP.
RNA extraction and Reverse transcription- PCR analysis
RNA extraction from tumor tissues was done[17]. Reverse
transcriptase (RT)-PCR was done using an RNA PCR kit
(Perkin Elmer Corporation, USA) following the manufac-
turer's instructions. PCR of the reverse transcribed product
was done using gene (FAT gene) specific primer pair (For-
ward 5' TTCAAAATAggTgAAgAgACAggTg 3' & reverse 5'
TTgTgATgAgACCTgTTTTAggATg 3') in PTC 200 thermal
cycler (MJ Research). Expression level of glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) was used as an
internal control. The primer pair used for GAPDH ampli-
fication was; Forward 5' CCAAggTCATCCATgACAACTTT-
ggT 3' & reverse 5' TgTTgAAgTCAgAggAgACCACCTg 3'.
Total of 18 astrocytic tumors (9 grade II and 9 grade IV)
and 2 cell-lines (U87MG & U373MG) were subjected to
RT-PCR analysis. Because of non-availability of suitable
samples, these were different from the tumors used for the
LOH studies. The amplification products were resolved in
2% agarose gel, documented in Gel Documentation Sys-
tem (Alpha Innotech Corporation, USA) and analyzed by
densitometry (using ChemiImager Software) for Inte-
grated Density Values (IDV). The densitometric value of
the GAPDH band was used to normalize the FAT band.
On the basis of IDV, tumors were divided into three
groups (with IDV of <0.75, 0.75–1.5 & >1.5). The mean
and standard deviation (SD) of the integrated density val-
ues (IDV) of the samples in these 3 groups was calculated
and the means compared to analyze and represent the
expression results.
Results
RAPD-fingerprinting of human astrocytic tumors and 
characterization
RAPD-PCR was done on 23 astrocytic tumors (12 Grade II
and 11 Grade IV) along with the corresponding normal
leucocyte DNA with 5 RAPD primers mentioned (Table
1). The alterations in the tumors were detected in the form
of loss/gain and/or change in the intensity of band. Most
of these alterations were unique to a particular sample
and were not consistent from tumor to tumor (Fig 1a).
With primer no. 80/07 loss of a band of ~500 bp was
detected in 33% (4/12) of the grade II tumors (Fig 1b–i).
We named the altered fragment – 80/07/A2 (80/07 is the
primer number; A2 is the sample number from which it
was first identified). Confirmation of consistent change
by Southern blotting with PCR-radiolabeled 80/07/A2
fragment showed that the altered fragment was unique in
the RAPD pattern in various samples mentioned (Fig 1b–
ii). The loss observed in the Southern blotting, corre-
sponded with the agarose gel profile. This further con-
firmed that the eluted band was similar to the band lost inBMC Cancer 2009, 9:5 http://www.biomedcentral.com/1471-2407/9/5
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the tumors. It was then cloned and the identity of the
clone was further confirmed by Southern hybridization
and sequencing. BLAST search of the sequence (Gen Bank
Accesion no. AF250763) showed 100% homology to FAT,
a putative tumor suppressor, at exon2-intron2 junction
on chromosome 4q34-q35 locus. FAT is homologue of
the Drosophila tumor suppressor gene fat and is a mem-
ber of the Cadherin gene family. It is a transmembrane
protein of nearly 4600 amino acid residue with 34 tan-
dem cadherin repeats, 5 EGF like repeats and a lamin A-G
domain.
Characterization of the RAPD primer binding sites
Two sample pairs, showing loss of band in the tumors,
when subjected to PCR using specific primer pair, a PCR
product of ~700 bp was obtained in all the samples
including both normal leukocyte and tumors (Fig 1c). The
PCR product of all the samples (normal and tumors) was
eluted, sequenced and searched for mutations or dele-
tions at the RAPD primer (80/07) binding regions (both
3' and 5') by performing BLAST 2 search with the FAT
gene sequence. No mutations or deletions were detected
at the primer binding regions of all the four samples (two
normal and two tumors) analyzed. Hence the reason for
the altered RAPD profile consistently and specifically at
this band in a high percentage of tumors could not be
ascertained. This however led us to investigate the region
by other methods, including LOH studies.
LOH analysis of the FAT locus
The microsatellite and SNP markers used for LOH analysis
are schematically represented in relation to the FAT gene
in Fig 2 and the primer sequences are shown in table 1. Of
the five microsatellite markers used, only the intragenic
marker i.e. D4S1295 was informative, while the other four
markers were uninformative. Of the 20 grade II astrocytic
(a) Representative RAPD gel profile showing alterations (arrows) in the form of loss/gain/change in intensity of band(s) in  tumor (T) as compared to normal leucocyte DNA (B) of the same patient, with different primers (primer nos. 80/01, 70/04,  70/01, 60/31) Figure 1
(a) Representative RAPD gel profile showing alterations (arrows) in the form of loss/gain/change in intensity of 
band(s) in tumor (T) as compared to normal leucocyte DNA (B) of the same patient, with different primers 
(primer nos. 80/01, 70/04, 70/01, 60/31). (b-i) RAPD gel profile of primer no. 80/07 indicating the frequent loss of a 500 bp 
band (arrow) in astrocytic tumors (T) as compared to the corresponding normal leucocyte DNA (B). (b-ii) Southern blot of 
the same RAPD profile, Southern hybridization was done to confirm the altered fragment with a radiolabeled probe prepared 
from 500 bp altered band eluted from the RAPD profile of normal DNA from another gel. (c) Amplification of normal (B) and 
tumor (T) DNA with loss of 500 bp band with specific primer pair designed to amplify the FAT gene corresponding to the 
altered band along with 100 bp on either side. Bands were eluted from the gel and sequenced to look for deletion(s)/muta-
tion(s) at RAPD primer binding sites. M represents molecular marker.BMC Cancer 2009, 9:5 http://www.biomedcentral.com/1471-2407/9/5
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tumors analysed with this intragenic marker (D4S1295),
only 6 samples were informative (heterozygous), of which
3 showed LOH. For grade IV astrocytic tumors, 5 out of 20
samples were informative, of which 2 showed LOH (Fig
3). A cumulative LOH status in both grade II and IV astro-
cytic tumors was 45.5% (5/11) (Table 2), however a defin-
itive LOH frequency could not be determined due to the
small number of informative samples. Hence we tried to
use intragenic SNP markers. Of the 10 SNP markers
selected for LOH analysis two markers (rs167853 &
rs6553016) did not work during standardization. Hence
LOH analysis was done with 8 SNP markers. With these
SNP markers, an increased number of informative (heter-
ozygous) samples were detected which were suitable for
LOH analysis.
Samples
The LOH analysis with SNP markers was done in 20 grade
II and 20 grade IV astrocytic tumors. Out of eight markers
used LOH was detected with six markers. A representative
LOH profile of all the samples with one marker (SNP
marker rs450320) is shown in Fig 4. Using these SNP
markers, 38/40 of the samples analyzed were informative.
Tumor IDs- A6, A7, A17, G7, G10 and G11 showed LOH
with more than one SNP markers studied (Table 3). LOH
observed in grade II astrocytic tumors was 42.10% (8/19)
and that of grade IV astrocytic tumors was similar, being
57.89% (11/19). Overall LOH frequency with SNP mark-
ers observed was 50% (19/38) in all (grades II and IV) the
samples studied (Table 4).
FAT expression study by RT-PCR
FAT expression was determined by means of reverse tran-
scriptase (RT)-PCR in 18 primary astrocytic tumors (9
grade II and 9 grade IV and two glioma cell lines (U87MG
and U373MG)). RT-PCR was done in duplicates. Densito-
metric analysis was done for the FAT mRNA expression,
normalized with GAPDH. There was no significant differ-
ence in the expression pattern of FAT with the grading of
the tumors (Fig 5). On the basis of IDV, tumors were
divided into three groups (with normalized integrated
density value (IDV) of <0.75, 0.75–1.5 and >1.5) (Fig 5C).
Most of the tumors were either with IDV of less than 0.75
(11/18) or greater than 1.5 (5/18) with very few (2/18) in
the intermediate cluster (IDV 0.75–1.5). The group with
IDV <.75 has been taken as the low expressor group, the
Schematic representation of the marker loci used for LOH analysis Figure 2
Schematic representation of the marker loci used for LOH analysis. (a) chromosome 4q35 loci with the microsatel-
lite markers from within and near to the FAT gene}. (b) Location of SNP markers in relation to the exons and introns of FAT 
gene. E indicates exon, numbered arrows indicate the SNP markers selected for LOH study. The Cluster id of SNP markers 
selected and used are mentioned.BMC Cancer 2009, 9:5 http://www.biomedcentral.com/1471-2407/9/5
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one with >1.5 has been taken as high expressor, while the
group from 0.75 to 1.5 was indeterminate and has not
been taken into account in the statistical comparison. The
mean normalized IDV for low expressing group
(IDV<0.75) was 0.41 (SD = 0.22) and that of high express-
ing group (IDV>1.5) was 2.18 (SD = 0.59). When we com-
pared the high and low expressors group, the difference
was statistically significant (p = 0.000001 by Students t
Test). However, both the glioma cell lines showed high
expression (IDV more than 1.5) of FAT mRNA.
Discussion
In this study we have used RAPD-PCR technique, a locus
non-selective DNA fingerprinting technique, to identify
alteration(s) in the astrocytic tumors of WHO grade II and
IV, taking peripheral blood leucocyte DNA of the same
patient as a normal control. With RAPD primer 80/07 a
loss of a band (500 bp) was detected in 33% (4/12) of the
grade II astrocytic tumors studied. The high frequency of
this alteration indicated that this alteration was a feature
associated with tumorigenesis in a significant proportion
of these tumors. Further characterization of the corre-
sponding band in normal DNA by Southern hybridiza-
tion, cloning, sequencing followed by homology search in
the public domain genome database using BLAST search
tool showed 100% homology to the FAT at exon2-intron2
junction on chromosome 4q34-q35 locus. It is a novel
finding as alteration of the FAT gene in astrocytic tumors
is not reported in literature till date.
Heterozygosity status in WHO grade II and IV astrocytic tumors with D4S1295 (intragenic to FAT) marker Figure 3
Heterozygosity status in WHO grade II and IV astrocytic tumors with D4S1295 (intragenic to FAT) marker. 
Heterozygous samples are shown in boxes with line patterns and samples showing LOH are in dotted boxes. B indicates con-
stitutive normal leucocyte DNA and T indicates tumor DNA. Out of 5 microsatellite markers used, only one marker 
(D4S1295) was informative and rest, all were uninformative (not shown in the figure). All photographs have been cropped and 
inverted to a white background for clarity.BMC Cancer 2009, 9:5 http://www.biomedcentral.com/1471-2407/9/5
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RAPD-PCR with multiple primers scans the whole
genome in an unbiased manner for any locus and has the
potential of detecting genomic regions that are altered and
as yet unidentified in astrocytic tumors. The RAPD prim-
ers which are short 10-mer random nucleotide sequence
acts both as forward and reverse primer. This single primer
binds to sites on both the complementary strands of the
genomic DNA and priming occurs depending on the
sequence match with the template DNA. The best of the
primer binding sites on the template often match only
about 6–8 bases out of 10 bases at the 3 'end of the
primer[18]. Amplification takes place from those regions
of the genome where the primer binds in correct orienta-
tion and the binding sites are within an amplifiable dis-
tance of each other and it requires small amount of DNA
(50–100 ng of DNA per PCR). This is important because
of the possibility of shearing and low retrieval after
extracting tumor DNA from cryostat sections.
The DNA most easily amplified usually constitutes shorter
(500 bp-2 kb), multiple products that could easily be
resolved on agarose gel. Scoring of the alterations [loss/
gain/change in the intensity of band(s)] can be done by
simply comparing the banding pattern of the tumor DNA
with the normal DNA. The fact that it is not restricted to a
defined locus enables its use to hunt for genomic regions
that are not identifiable by published literature or not
immediately obvious after analysis of sequences. The pos-
sibility of obtaining non-reproducible results in RAPD
analysis has been discussed in published literature[19].
However, this is not insurmountable and RAPD results are
reproducible, as evident from the available literature
using this technique[10,11,14,20-22]. In this work all the
required precautions[23] have been taken to maintain the
reproducibility of the results. Altered bands were checked
at least thrice for reproducibility and each alteration was
scored by two independent observers. To avoid false pos-
itives, we compared the intensities of the preceding and
succeeding bands of the altered band in both the normal
and tumor DNA while scoring the alteration in the tumor.
After localization of the altered RAPD fragment to the FAT
gene locus, and no changes being observed in the
sequence of the primer binding regions, further analysis
was done using locus specific markers of microsatellite
and SNP-RFLP markers to determine the LOH status in the
tumors. Frequent LOH of a specific chromosomal region
is considered to be an indicator of a loss of a closely linked
tumor suppressor gene. LOH of the FAT  locus was
detected in 48% (5/11) of the informative samples with
the intragenic (D4S1295) marker. Four markers flanking
the gene were uninformative (homozygous). Using 8
intragenic SNP markers, 38 out of 40 samples initially
taken for LOH analysis were found to be informative and
LOH was detected in 50% (19/38) of the informative
samples. To the best of our knowledge till date there is no
literature available directly linking the FAT locus to glial
tumorigenesis. SNP analyses in gliomas have been per-
formed by many researchers on other specific chromo-
somal loci, using SSCP and PCR-RFLP methods and LOH
status was correlated to tumor stage and progres-
sion[24,25]. In our study, the use of SNP-RFLP has led to
a better detection of LOH in both grade II and IV astrocy-
tomas. The similar frequency of LOH of this locus in both
low and high grade tumors indicates that this locus is
probably affected early in tumorigenesis.
LOH and/or deletion of the chromosome 4q34-35 region
(which harbors FAT gene) using microsatellite markers
was earlier found in grade IV Glioblastoma Multiforme
(GBM)[26], though the gene itself was never implicated.
Many other tumors like Small Cell Lung Carcinoma[27],
hepatocellular carcinoma[28] and cervical carcinoma[29]
etc showed alterations in this chromosomal region. Simi-
larly CGH analysis also showed loss of Chromosome
4q34-q35 locus in hepatocellular carcinoma[30] and oral
cancer[31]. In all these LOH studies, a significant associa-
tion of 4q34-35 region with increased risk of progression
to higher grade or with the malignancy of the tumors was
suggested. Since the FAT gene is located in this region it
may have an important role to play in the development
Table 2: Summary of LOH analysis of FAT gene locus in astrocytic tumors (20 grade II and 20 grade IV) with microsatellite markers. 
Microsatellite markers D4S D4S3173 D4S2827 D4S1295 D4S2643 D4S2672
Informative samples Grade II U U 6/20 (30%) U U
Grade IV U U 5/20 (25%) U U
LOH per informative samples Grade II U U 3/6 (50%) U U
Grade IV U U 2/5 (40%) U U
Total LOH per informative samples
(Grade II & IV)
UU 5/11 (45.45%) UU
Only one marker (D4S1295) was informative, other 4 markers were uninformative (U).BMC Cancer 2009, 9:5 http://www.biomedcentral.com/1471-2407/9/5
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and progression of various tumors including astrocytic
tumors. Our results, showing deletion of FAT locus iden-
tified with RAPD technique followed by detection of fre-
quent LOH of the locus using microsatellite and
intragenic SNP markers, further strengthen the possibility
of association of the locus in the development or progres-
sion of the astrocytic tumors.
Expression of FAT was checked in a panel of 18 astrocytic
tumors (9 Grade II and 9 Grade IV), On the basis of IDV,
we could cluster most of the tumors in two groups, one of
which has comparatively lower FAT expression then the
other group. However the two glioma cell lines showed
high expression of FAT. There is no literature n the pattern
of FAT expression in normal human brain. Also not much
is known about FAT regulation in primary glial tumors
and cell lines. How FAT  is regulated in cell lines and
whether FAT expression in cell lines is a true reflection of
the satus in primary tumors is again not clear and needs to
be studied.
FAT is a human orthologue of Drosophila tumor suppres-
sor gene fat and is a member of the cadherin gene family.
The fat gene in Drosophila is essential for controlling cell
proliferation during its development. Disruption of fat
causes imaginal disc tumors in Drosophila[32]. The fat
Representative gel photographs indicating loss of heterozygosity (LOH), no LOH (NLOH) and uninformative (U) results in high  (G) and low (A) grade astrocytic tumors (20 each) with one SNP marker (rs450230) Figure 4
Representative gel photographs indicating loss of heterozygosity (LOH), no LOH (NLOH) and uninformative 
(U) results in high (G) and low (A) grade astrocytic tumors (20 each) with one SNP marker (rs450230). B indi-
cates normal leucocyte DNA and T indicates tumor DNA. NA is not amplified. All photographs have been cropped and 
inverted to a white background for clarity.BMC Cancer 2009, 9:5 http://www.biomedcentral.com/1471-2407/9/5
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gene was first discovered in Drosophila followed by the
identification of its orthologue in man[33], rat[34],
mouse[35] and zebrafish[36]. In humans, the tissue dis-
tribution of FAT transcripts in fetal and adult tissues has
been analyzed in detail by Dunne et al[33] who showed
that FAT mRNA is present in many epithelial and some
endothelial and smooth muscle cells. In human fetal tis-
sues, high levels of FAT transcripts were found in kidney,
lungs, and eye epithelia, which were down regulated in
the corresponding adult tissues. Expression analysis in
mouse [35] revealed mFAT expression early in pre-
implantation stage (eight cell stage). In situ expression
analyses showed wide spread expression throughout post-
implantation development, notably in the limb buds,
bronchial arches, and in the proliferating ventricular
zones in the brain. RT-PCR analysis of mFAT in adult
mouse tissues detected widespread expression in many
tissues and cell types. They suggested the role of FAT in
cell proliferation and differentiation in mouse. FAT also
serves as a proximal element of signaling pathways neces-
sary for cell migration [37,38]. FAT  tumor suppressor
gene is an upstream regulator of the Salvador-Wart-Hippo
Table 3: Loss of heterozygosity analysis of the FAT gene with 8 intragenic SNP markers in 20 grade II (A) and 20 grade IV (G) 
astrocytic tumors.
Low grade Diffuse Astrocytoma (Grade II)
SNP 
markers
A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 A13 A14 A15 A16 A17 A18 A19 A20
rs2276930 U U U U U U U U UUUUUUUUUUUU
rs3733414 NL NL UUUL L NL NL NL NL NL NL NL NL NL U NL NL U
rs455600 UUUUUL U NL NL U NL U NL UUULN LUU
rs213090 NL NL UU NL U L U NL U NL UUUUULN LL U
rs450320 U L U LN LU NL U LN LU NL U NL NL NL U NL U L
rs7663350 NL NL UU NL NL UUU U UNL UUU NL UUU NL
rs1193110 U NL U U U U U U UUUUUUUUUU NL U
rs1298865 U U U U U U U U UUUUUUUUUUUU
Glioblastoma multiforme (Grade IV)
SNP 
markers
G1 G2 G3 G4 G5 G6 G7 G8 G9 G10 G11 G12 G13 G14 G15 G16 G17 G18 G19 G20
rs2276930 U U U U U U U U UUUUUUUUUUUU
rs3733414 UUUU NL U L UU LLUU NL NL UUU NL NL
rs455600 NL U NL UUUL U L U NA NL UUUUUUU NL
rs213090 L L UUUUU NL UU NL U NL UUUUUUL
rs450320 NL NL L L U NL U LN AN L L UU NL UUL UUU
rs7663350 UU NL UU NL U UN L UUUUUUUU NL NL NL
rs1193110 UUUUUUUUU L U NL UUUUUUUU
rs1298865 UUUUUUUUU U U L UUUUUUUU
L is loss of heterozygosity, NL is no loss of heterozygosity, U is uninformative and NA is not analysed. Loss of heterozygosity was detected in 42% 
of grade II and 58% of grade IV astrocytic tumors.BMC Cancer 2009, 9:5 http://www.biomedcentral.com/1471-2407/9/5
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(SWH) signaling pathway [39,40] which is well estab-
lished in Drosophila. This pathway is conserved in human
but the role of FAT in human cancer is not clear and not
much literature is available about FAT and its effect on
SWH pathway in humans. The downstream effector mol-
ecule of SWH pathway is YAP. Like TGFβ, in mammal,
SWH pathway via YAP is found to have both oncogenic
[41-43] and tumor suppressor effects [44]. FAT  might
have an important role in oncogenesis in humans.
Recently, Nakaya et al[31] has shown homozygous dele-
tion of FAT gene in oral cancer using CGH-array and low
mRNA expression of FAT gene suggested importance of
FAT in the development of oral cancer. Role of FAT gene
is also suggested in development of fallopian tube cancer
in a patient of MRKH (Mayer Rokitansky Kuster Hauser)
syndrome [45]. Based on the signaling pathways linked
with FAT, with several of the signaling pathways associ-
ated with Drosophila ortholgues have been worked out in
humans, a comparative study of signaling pathways and
other properties of the two tumor groups (high and low
expressing) would be useful and is planned for the future.
Conclusion
Our results show frequent LOH at the FAT locus in pri-
mary human glial tumors. Based on FAT expression, these
tumors may be divided into two groups showing low and
high expression respectively. Our results also show that
RAPD analysis is a reliable method in scanning the
genome for identification of novel genomic alterations in
tumors. Not only can it address the issues related to the
overall extent and nature of genomic instability, but spe-
cific regions affected in a particular tumor type can also be
identified. To further understand the functional role of
FAT gene in tumorigenesis, we are in the process of ana-
lyzing its expression and methylation status in primary
astrocytic tumors and in cell lines. We are also trying to
determine whether the low and high expressor groups
have any differences with regard to altered signaling path-
ways (especially the SWH pathway) and in the tumor phe-
notype.
Abbreviations
RAPD: Random Amplification of Polymorphic DNA; DA:
Low grade diffuse astrocytoma; AA: Anaplastic astrocy-
toma; GBM: Glioblastoma Multiforme; LOH: Loss of het-
erozygosity; SNP: Single Nucleotide Polymorphism;
RFLP: Restriction fragment length polymorphism; RT-
PCR: Reverse transcriptase polymerase chain reaction;
TSG: tumor suppressor gene; GAPDH: Glyceraldehyde: 3:
phosphate dehydrogenase.
Table 4: Summary of LOH analysis of FAT gene locus in astrocytic tumors (20 grade II and 20 grade IV) by RFLP using SNP markers. 
Summary of LOH detected with each SNP markers
SNP-Markers rs22 76930 rs37 33414 rs45 5600 rs21 3090 rs45 0320 rs76 63350 rs11 93110 rs12 98865
Informative 
samples
Grade II 0/20 (0%) 15/20 (75%) 7/20 (35%) 9/20 (45%) 12/20 (60%) 7/20 (35%) 2/20 (10%) 0/20 (0%)
Grade IV 0/20 (0%) 8/20 (40%) 6/20 (30%) 6/20 (30%) 10/20 (50%) 0/20 (0%) 2/20 (10%) 1/20 (5%)
LOH per 
informative 
samples
Grade II 0/20 (0%) 2/15 
(13.33%)
2/7 (28.57%) 3/9 (33.33%) 4/12 
(33.33%)
0/7
(0%)
0/2
(0%)
0/0
(0%)
Grade IV 0/20 (0%) 3/8 (37.5%) 2/6 (33.33%) 3/6 (50%) 5/10 (50%) 0/0
(0%)
1/2 (50%) 1/1 (100%)
Total LOH
(Grade II & IV)
0/20 (0%) 5/23
21.73%
4/13
30.73%
6/15
40%
9/22
40.90%
0/7
(0%)
1/4
25%
1/1 100%
LOH per informative samples
Samples Grade II (N = 20) Grade IV (N = 20) Grade II&IV (N = 40)
Overall SNP LOH per
informative samples
8/19*
(42.10%)
11/19*
(57.89%)
19/38
(50%)
And SNP LOH detected per informative samples (Grade II and IV) with all SNP markers.
* In both grade II and grade IV one sample each were uninformative with all the SNP markers used.BMC Cancer 2009, 9:5 http://www.biomedcentral.com/1471-2407/9/5
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